Turn Therapeutics Inc. Common Stock (TTRX)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Turn Therapeutics traded at $10.60, giving a $315.8M market cap. I start with the business: it is a two-employee pharmaceutical developer for skin, nails, and eyes. In the filed figures, revenue is n/a every period I can see, and every period shows a loss. In fiscal 2024, the year ended 2024-12-31, net income was -$1.8M and diluted EPS was -$0.07. In fiscal 2025, the year ended 2025-12-31, the loss widened to -$3.2M, or -$0.12 per diluted share. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was -$5.8M and diluted EPS was -$0.20. That is not a Graham-style earnings record. FairStock calculations show P/E -37.86, P/B 530.00, ROE -686.28%, ROCE -50.27%, D/E 8.91, FCF -$4.5M, and FCF yield -1.4%. The Piotroski F-Score is 1/9 and FairStock Score is 28/100, while Altman Z-Score is 9.35—an odd mix, but I do not see a durable moat or pricing power from these figures. The Lynch category is none because only two years of filed results are available. With no revenue, negative free cash flow, and a market value far above book value, there is no margin of safety in the current numbers. The story may be about future delivery technology, but the financials do not yet demonstrate commercial success. I would want evidence of revenue, narrower losses, and self-funding before calling this anything but speculative.

In plain English: Turn Therapeutics is a small healthcare company trying to develop treatments for skin, nail, and eye problems. Based on its filed results, it has no reported revenue and has been losing money, with losses in fiscal 2025 and the first half of fiscal 2026. At $10.60 a share, the price looks very high compared with its tiny accounting value and negative earnings, so it looks expensive versus its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer